Zentalis Pharmaceuticals, Inc. Common Stock
ZNTLZentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for cancers with high unmet medical needs. The company's approach involves designing small molecule therapeutics that inhibit cancer-driving proteins, with a focus on oncology indications such as solid tumors and hematologic malignancies.
Company News
Over 25 companies are developing 32+ pipeline drugs for osteosarcoma treatment, with significant focus on innovative approaches including Phase III product HS-20093 (B7-H3-targeted ADC), TGF-β1 inhibitors, and CAR-T therapies. The report highlights strong R&D activity and substantial unmet medical needs in this primary malignant bone tumor space.
Zentalis Pharmaceuticals granted non-qualified stock options for 191,000 shares to two newly hired employees at an exercise price of $3.98 per share. The company is strengthening its commercial leadership team and advancing its registrational program for azenosertib, a first-in-class WEE1 inhibitor, in platinum-resistant ovarian cancer treatment.
Zentalis Pharmaceuticals granted 26,000 non-qualified stock options to a newly hired employee on May 1, 2026, with an exercise price of $4.09 per share under the 2022 Inducement Plan. The options have a 10-year term and vest over four years, subject to continued employment.
Zentalis Pharmaceuticals granted non-qualified stock options to purchase 36,000 shares to two newly hired employees on April 1, 2026, with an exercise price of $2.57 per share. The options vest over four years under the company's 2022 Inducement Plan.
The oncology landscape is experiencing rapid regulatory advancement as precision medicine and genomics expand significantly. Multiple biotech companies are advancing cancer therapies toward accelerated FDA approvals in 2026, with the precision medicine market projected to grow from $138.67 billion in 2026 to $537.17 billion by 2035. Key developme...